Yes, several major pharmaceutical companies have been convicted or have pleaded guilty to commercial fraud: GlaxoSmithKline settled for about $3 billion in 2012, Pfizer for $2.3 billion in 2009, Johnson & Johnson for more than $2.2 billion in 2013, all for the illegal promotion of medicines. These are judicial facts, dated and verifiable. But a convicted marketing fraud does not prove that a medicine is ineffective, nor that a vaccine is dangerous: these are two distinct questions that must be carefully separated.
Definition: a Big Pharma conviction is a court decision or a settlement agreement (often concluded with the U.S. Department of Justice) by which a company acknowledges, or is accused of, illegal commercial practices — off-label promotion, concealment of safety data, hidden payments to physicians. It judges sales practices, not the therapeutic value of a molecule.
There are two symmetrical ways of being wrong about the pharmaceutical industry. The first is naivety: believing that a company worth tens of billions would never have lied or corrupted a physician. The second is paranoia: sliding into the idea that, because some companies committed fraud, all medicines are poisons and all of medicine a deception. This investigation rejects both.
The golden rule fits in one sentence: a documented marketing fraud does not condemn the molecule. An antibiotic saves lives even if the commercial campaign around it was judged fraudulent. Risperdal, Bextra and Paxil had legitimate indications; what was condemned was the way they were sold, not their existence. Confusing the two betrays the victims of the fraud and feeds a distrust that, paradoxically, protects the fraudsters by drowning their specific acts in a fog of general suspicion.
In July 2012, GlaxoSmithKline agreed to plead guilty and to settle, for $3 billion, allegations brought by the U.S. Department of Justice (DOJ). The charges included the illegal promotion of antidepressants (Paxil, Wellbutrin) for uses not approved by the FDA — including the prescription of Paxil to minors — and the failure to report safety data concerning the diabetes drug Avandia. The DOJ described this settlement as the largest health care fraud resolution concluded in the United States to that date.
In September 2009, Pfizer settled, for $2.3 billion, allegations of fraudulent promotion; its subsidiary Pharmacia & Upjohn pleaded guilty to a criminal offence related to the promotion of Bextra, an anti-inflammatory, for unapproved uses and doses. In November 2013, Johnson & Johnson and its subsidiaries agreed to a settlement of more than $2.2 billion for civil and criminal allegations related to the promotion of Risperdal, an antipsychotic, to elderly people and children, and to the payment of kickbacks to physicians and a pharmacy chain.
These settlements are almost always accompanied by a Corporate Integrity Agreement concluded with the Office of Inspector General of the Department of Health: obligations of compliance, training, audit and reporting, generally for five years, under penalty of exclusion from public programmes. The very existence of this mechanism is the institutional admission that the fine alone does not suffice to correct behaviour. A point of honesty is nonetheless required: these amounts also reflect the size of the markets concerned and the intensity of U.S. public action against fraud against Medicare and Medicaid; adding them up to produce a spectacular figure would be a prosecutor's shortcut, not a clerk's.
No case better illustrates the line between medicine and marketing than that of OxyContin: the product had a real use in pain relief, and it was its commercialisation that was judged criminal. As early as May 2007, the Purdue Frederick Company and three of its executives pleaded guilty, before a federal court in Virginia, to misleading the public, physicians and regulators about the risk of abuse and dependence of this powerful opioid, for a settlement of about $600 million.
In October 2020, Purdue Pharma again pleaded guilty to federal criminal charges — a conspiracy to defraud the United States and to violate the Food, Drug, and Cosmetic Act, and two counts of conspiracy to violate the Anti-Kickback Statute —, as part of a global resolution announced by the DOJ and tied to its bankruptcy proceedings. The Sackler family, owner of Purdue, was the subject of intense litigation: successive agreements provided for payments of several billion in exchange for protection against civil lawsuits, a provision that the U.S. Supreme Court invalidated on 27 June 2024 in Harrington v. Purdue Pharma, ruling that the bankruptcy code did not authorise such a non-consensual release for third parties.
The opioid crisis is documented by federal health authorities: the Centers for Disease Control and Prevention (CDC) record hundreds of thousands of overdose deaths involving opioids over the past two decades. OxyContin is thus the textbook case of this investigation: one and the same object can be a legitimate relief for a patient at the end of life and the instrument of a public health catastrophe, depending on how it is presented and how its sale is organised. Condemning the marketing fraud is not condemning pain relief; it is demanding that the truth about the risks be told.
Vioxx (rofecoxib), an anti-inflammatory of the coxib class marketed by Merck, was voluntarily withdrawn from the global market in September 2004, after the results of a clinical trial (the APPROVe study) showed an increased risk of cardiovascular events in patients treated long-term. In 2011, the company settled with the DOJ, for $950 million and with a criminal component (the subsidiary Merck Sharp & Dohme having pleaded guilty to a violation of the Food, Drug, and Cosmetic Act), allegations relating to the promotion of Vioxx for unapproved uses and to statements about its cardiovascular safety.
The Vioxx case illustrates a grey area different from pure fraud: that of the delay between the appearance of a safety signal and its public and regulatory handling. The question is not "was the medicine diabolical" — it genuinely relieved joint pain — but "did the system handle the safety information with the required speed and transparency?" This is a question of information governance, and it justifies no generalised distrust of anti-inflammatories.
To understand why the same charges recur from one company to another, the legal mechanism must be named. In the United States, the FDA approves a medicine for specific indications. A physician may, in the exercise of their craft, prescribe "off-label"; by contrast, it is illegal for a manufacturer to actively promote a medicine for an unapproved use. It is this promotion by the manufacturer — and not the prescription by the physician — that formed the basis of the major GSK, Pfizer and Johnson & Johnson settlements.
Many of these cases were triggered by internal whistleblowers, via the U.S. False Claims Act (the so-called qui tam procedure), which allows an employee to report fraud at the expense of public programmes and to receive a share of the recovery. The techniques described in the indictments resemble one another from one file to the next: funding of medical opinion leaders, slanted conferences, prescription kickbacks, targeting of vulnerable populations. This recurring repertoire outlines a business model, independently of any particular product — but it says nothing about the intrinsic efficacy of the molecules concerned.
Beyond the fines, an even better-documented critique concerns the production of scientific evidence itself — and it comes from within medicine, not from its adversaries. The physician Ben Goldacre, in Bad Pharma (2012), assembled an indictment grounded in the literature: trials with negative results left unpublished, articles written by industry ghostwriters then signed by academics (ghostwriting), slanted protocols. His central argument is not that medicines are false, but that the missing data distorts the assessment that physicians and patients can make of them.
The problem of unpublished trials gave rise to the AllTrials campaign (2013), which demands the registration of all clinical trials and the publication of their results — a requirement now partly translated into regulatory obligations. The epidemiologist John Ioannidis published in 2005, in PLoS Medicine, the article "Why Most Published Research Findings Are False," one of the most cited in the biomedical literature: it analyses how small sample sizes, conflicts of interest and the pressure to publish can inflate the proportion of results that do not replicate. It is an internal methodological critique, not a rejection of science.
The most telling example is that of the antidepressants analysed by Turner and colleagues (2008, NEJM): of all the trials registered with the FDA, nearly all the trials judged positive had been published, while a large share of the negative trials had not been or had been presented in a favourable light. The literature accessible to prescribers therefore gave a more advantageous picture than the totality of the data actually available. The medicine was not "false"; the image the literature conveyed of it was simply incomplete.
These works converge towards a measured conclusion: the problem is not that "science lies," but that incomplete access to data degrades the quality of decisions. It is exactly the opposite of an anti-science posture — it is a demand for more science, better published and independently verifiable. Recognising a publication bias means defending the scientific method against what corrupts it, not rejecting it.
A final, more structural area concerns the relationship between the companies and the authorities supposed to oversee them. In the United States, since the Prescription Drug User Fee Act (PDUFA, 1992), a substantial part of the budget the FDA devotes to evaluating medicines comes from user fees paid by industry. The device was designed to speed up the review of files; it also creates a partial budgetary dependence on the regulated entities, which is regularly debated.
The concept of regulatory capture — a situation in which an authority comes to serve the interests of the sector it oversees — is an established object of study in political economy, theorised notably by George Stigler (1971). It provides a framework for analysis, not an automatic accusation: capture is a structural possibility to watch, not a verdict. The remedy is not distrust of the agencies — which have also withdrawn dangerous products and protected millions of patients — but the strengthening of their financial independence and their transparency.
These markers turn a diffuse indignation into a rigorous reading. They make it possible to hold, at once, that some companies gravely committed fraud and that evidence-based medicine remains one of the greatest achievements of our civilisation. Our full investigation details each affair, its references and its dates, for anyone who wants to verify piece by piece.
How much did GSK, Pfizer and J&J pay? GlaxoSmithKline settled for $3 billion in 2012, Pfizer for $2.3 billion in 2009 and Johnson & Johnson for more than $2.2 billion in 2013, as part of agreements with the U.S. Department of Justice for the illegal promotion of medicines.
Do these convictions prove that the medicines are dangerous? No. They concern commercial practices — off-label promotion, concealment of data, kickbacks — and not the therapeutic value of the molecules. The products concerned most often had legitimate indications; it was the way they were sold that was judged.
What is off-label marketing? It is the active promotion, by a manufacturer, of a medicine for a use that the health authority has not approved. A physician may prescribe off-label, but an industry player has no right to promote it: this distinction is at the heart of the major convictions.
What is publication bias? It is the tendency for positive results to be published more than negative or null results, which gives prescribers a more favourable picture than the totality of available data. Recognising it means demanding more scientific transparency, not rejecting science.
Was the Sackler family convicted? Purdue Pharma pleaded guilty several times (2007, 2020). In June 2024, the U.S. Supreme Court invalidated the agreement that would have protected members of the Sackler family against civil lawsuits, reopening the question of their financial liability.
Is denouncing Big Pharma being anti-vaccine? No, and it is even the opposite. Documenting specific and verified marketing fraud is a rigorous approach; sliding into the idea that all vaccines or treatments are dangerous is disinformation that this investigation explicitly rejects. Demanding the integrity of commercial practices means defending medicine, not rejecting it.
GlaxoSmithKline settled for $3 billion in 2012, Pfizer for $2.3 billion in 2009 and Johnson & Johnson for more than $2.2 billion in 2013, as part of agreements with the U.S. Department of Justice for the illegal promotion of medicines.
No. They concern commercial practices — off-label promotion, concealment of data, kickbacks — and not the therapeutic value of the molecules. The products concerned most often had legitimate indications; it was the way they were sold that was judged.
It is the active promotion, by a manufacturer, of a medicine for a use that the health authority has not approved. A physician may prescribe off-label, but an industry player has no right to promote it: this distinction is at the heart of the major convictions.
It is the tendency for positive results to be published more than negative or null results, which gives prescribers a more favourable picture than the totality of available data. Recognising it means demanding more scientific transparency, not rejecting science.
Purdue Pharma pleaded guilty several times (2007, 2020). In June 2024, the U.S. Supreme Court invalidated the agreement that would have protected members of the Sackler family against civil lawsuits, reopening the question of their financial liability.
No, and it is even the opposite. Documenting specific and verified marketing fraud is a rigorous approach; sliding into the idea that all vaccines or treatments are dangerous is disinformation that this investigation explicitly rejects. Demanding the integrity of commercial practices means defending medicine, not rejecting it.
Dossier : Big Pharma & souveraineté alimentaire
MINI15: Big Pharma — La Corruption Documentée
Accueil · Collection · Journal · Dossiers · Sources